Soni Medicare

Why is Soni Medicare Ltd falling/rising?

As of 31-Jul, Soni Medicare Ltd's stock price is rising to Rs 57.87, reflecting a 4.99% increase. This short-term recovery follows a significant 20.59% gain over four days, despite a longer-term decline of 42.53% year-to-date.

As of 31-Jul, Soni Medicare Ltd's stock price is rising, currently at Rs 57.87, reflecting a change of 2.75 (4.99%) upward. This increase can be attributed to several factors. Notably, the stock has been on a positive trajectory, gaining for the last four consecutive days and achieving a total return of 20.59% during this period. Additionally, today's performance has outperformed the sector by 5.47%.<BR><BR>In the context of recent performance, the stock has shown a significant increase of 14.73% over the past week, which is considerably higher than the Sensex's 2.68% increase during the same timeframe. However, it is important to note that the stock has experienced a decline of 17.56% over the past month and a year-to-date drop of 42.53%. Despite these longer-term declines, the current upward movement indicates a short-term recovery phase.<BR><BR>The stock's intraday high of Rs 57.87 also suggests strong trading activity, although there has been a decrease in investor participation, with delivery volume falling by 48.75% against the 5-day average. This could indicate a potential concern regarding sustained interest from investors. Nevertheless, the current rise in stock price reflects a positive short-term sentiment among traders.

Which are the latest news on Soni Medicare?

Should I buy, sell or hold Soni Medicare Ltd?

What does Soni Medicare do?

Soni Medicare Ltd is a micro-cap company in the hospital industry, incorporated in 1988, with recent net sales of 6 Cr and a market cap of INR 31 Cr. It reported a net profit of 0 Cr for the quarter ending March 2026.

Overview: <BR>Soni Medicare Ltd operates in the hospital industry and is categorized as a micro-cap company.<BR><BR>History: <BR>Soni Medicare Limited was incorporated in 1988 as 'Soni Hospital Private Limited' and changed its name to Soni Medicare Private Limited in 1995. It later became a public limited company, adopting the name Soni Medicare Limited. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 6 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 31 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 24 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 9.62 <BR>Return on Equity: -199.00% <BR>Price to Book: 31.13<BR><BR>Contact Details: <BR>Address: 38 Kanota Bagh, Jawahar Lal Nehru Marg Jaipur Rajasthan : 302004 <BR>Tel: 91-141-5163700 <BR>Email: jpsassociates@hotmail.com <BR>Website: http://www.sonihospitals.com

How big is Soni Medicare?

As of 10th June, Soni Medicare Ltd has a market capitalization of 31.00 Cr, with Net Sales of 24.70 Cr and a Net Profit loss of 2.71 Cr over the latest four quarters. Shareholder's Funds are 1.30 Cr and Total Assets are valued at 22.17 Cr as of March 2025.

As of 10th June, Soni Medicare Ltd has a market capitalization of 31.00 Cr and is classified as a Micro Cap company.<BR><BR>In the latest four quarters, Soni Medicare reported Net Sales of 24.70 Cr. However, the company experienced a loss of 2.71 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025, where Shareholder's Funds amounted to 1.30 Cr and Total Assets were valued at 22.17 Cr.

Who are in the management team of Soni Medicare?

The management team of Soni Medicare includes Bimal Roy Soni (Chairman & Managing Director), Anju Soni (Director), and Independent Directors Mahavir Prasad Yadav, Mamta Sharma, and Naveen Sanghi, along with Juhi Gurnani (Company Secretary & Compliance Officer).

The management team of Soni Medicare includes the following individuals:<BR><BR>- Anju Soni, who serves as a Director.<BR>- Bimal Roy Soni, who is the Chairman & Managing Director.<BR>- Mahavir Prasad Yadav, an Independent Director.<BR>- Mamta Sharma, also an Independent Director.<BR>- Naveen Sanghi, another Independent Director.<BR>- Juhi Gurnani, who holds the position of Company Secretary & Compliance Officer.<BR><BR>If you have any more questions about Soni Medicare or its operations, feel free to ask!

Who are the peers of the Soni Medicare?

Soni Medicare's peers include Fortis Malar, Shanmuga Hospital, KK Shah Hospital, and others, with varying management and growth risks. Soni Medicare has a 1-year return of 43.70%, significantly outperforming peers like Global Longlife, which has a return of -55.83%.

Peers: The peers of Soni Medicare are Fortis Malar, Shanmuga Hos., KK Shah Hospital, Global Longlife, Broach Lifecare, Aatmaj Health, Nidan Laborator., Sangani Hospital, Docmode Health, and Maitreya Medica.<BR><BR>Quality Snapshot: Below Average management risk is observed at Fortis Malar, Soni Medicare, KK Shah Hospital, Global Longlife, Nidan Laborator., Docmode Health, and Maitreya Medica. Average management risk is found at Shanmuga Hos. and Aatmaj Health, while Sangani Hospital displays Excellent management risk. Below Average growth is noted at Fortis Malar, Soni Medicare, KK Shah Hospital, Global Longlife, Broach Lifecare, Nidan Laborator., Docmode Health, and Maitreya Medica, while Average growth is seen at Shanmuga Hos. and Aatmaj Health, with Sangani Hospital showing Excellent growth. Capital Structure ratings include Excellent at Shanmuga Hos., Good at KK Shah Hospital, Broach Lifecare, and Aatmaj Health, and Below Average at the rest.<BR><BR>Return Snapshot: Soni Medicare has a 1-year return of 43.70%, while Global Longlife has the lowest at -55.83%. Compared to its peers, Soni Medicare's return is significantly higher. Additionally, Global Longlife, Broach Lifecare, and Fortis Malar have negative six-month returns.

When is the next results date for Soni Medicare Ltd?

The next results date for Soni Medicare Ltd is 30 May 2026.

The next results date for Soni Medicare Ltd is scheduled for 30 May 2026.

How has been the historical performance of Soni Medicare?

Soni Medicare has experienced steady revenue growth, with net sales increasing from 14.67 Cr in Mar'19 to 29.84 Cr in Mar'25, but continues to face profitability challenges, reporting a profit after tax of -0.19 Cr in Mar'25 despite improved operational efficiency. Total liabilities and assets rose to 22.17 Cr, indicating balanced growth.

Answer:<BR>The historical performance of Soni Medicare shows a fluctuating trend in its financial metrics over the years, with notable changes in revenue and profitability.<BR><BR>Breakdown:<BR>Soni Medicare's net sales have increased from 14.67 Cr in Mar'19 to 29.84 Cr in Mar'25, indicating a steady growth trajectory. Other operating income has also risen, reaching 1.35 Cr in Mar'25 from negligible amounts in previous years. Total operating income has seen a similar upward trend, climbing to 31.19 Cr in Mar'25 from 14.67 Cr in Mar'19. However, total expenditure has also increased, leading to an operating profit (PBDIT) of 1.27 Cr in Mar'25, a recovery from a loss of 0.25 Cr in Mar'24. Despite this, the company has reported a profit before tax of -0.22 Cr in Mar'25, an improvement from -1.63 Cr in Mar'24, and a profit after tax of -0.19 Cr, reflecting ongoing challenges. The company's total liabilities rose to 22.17 Cr in Mar'25, up from 19.66 Cr in Mar'24, while total assets increased to 22.17 Cr as well, indicating a balance between growth in assets and liabilities. Cash flow from operating activities turned positive at 1.00 Cr in Mar'25, contrasting with previous years where it was negative, suggesting improved operational efficiency. Overall, while Soni Medicare has shown growth in sales and operating income, it continues to face challenges in achieving profitability.

Is Soni Medicare overvalued or undervalued?

As of November 17, 2025, Soni Medicare is considered risky and overvalued due to troubling financial ratios, including a PE ratio of -43.73 and an EV to EBITDA of 51.80, despite a year-to-date stock return of 210.97% that lags behind the Sensex's 8.72% return.

As of 17 November 2025, Soni Medicare's valuation grade has moved from attractive to risky, indicating a significant shift in its financial outlook. The company appears to be overvalued, particularly given its troubling ratios, including a PE ratio of -43.73, an EV to EBITDA of 51.80, and a ROE of -76.74%. These figures suggest that the company's earnings are not only negative but also that it is trading at a high multiple relative to its earnings before interest, taxes, depreciation, and amortization.<BR><BR>In comparison to its peers, Soni Medicare's valuation stands out unfavorably. For instance, Apollo Hospitals, which is rated attractive, has a PE ratio of 64.41 and an EV to EBITDA of 33.85, while Max Healthcare is categorized as very expensive with a PE of 77.22 and an EV to EBITDA of 53.09. The stark contrast in these ratios highlights Soni Medicare's riskier position within the industry. Additionally, despite a remarkable year-to-date stock return of 210.97%, the recent performance has lagged behind the Sensex, which returned 8.72% over the same period. This combination of factors reinforces the conclusion that Soni Medicare is currently overvalued.

Are Soni Medicare latest results good or bad?

Soni Medicare's latest results show a mixed performance; while profitability has improved with a Profit After Tax of Rs 0.06 crore compared to a loss last year, the company faces challenges with declining net profit and a low Debtors Turnover Ratio, leading to a 'Sell' rating from MarketsMOJO.

Soni Medicare's latest results present a mixed picture. On one hand, the company has shown a notable improvement in profitability, reporting a Profit After Tax (PAT) of Rs 0.06 crore for the latest six-month period, a significant turnaround from a loss of Rs 1.42 crore in the previous year. This indicates that Soni Medicare has managed to surpass its PAT from the last year within just half a year, which is a positive development.<BR><BR>However, the overall financial performance for the quarter ending June 2025 has been flat, with a decline in its performance score from 3 to 2 over the past three months. Additionally, while net sales have grown by 5.97% compared to the previous quarter, the standalone net profit has seen a drastic decline of 182.86%. This suggests that while sales are increasing, the company is struggling to translate that into profit effectively.<BR><BR>Moreover, the Debtors Turnover Ratio has reached its lowest point in the last five half-yearly periods at 3.41 times, indicating challenges in managing debts and potentially impacting cash flow and operational efficiency. The stock has also been rated as a 'Sell' by MarketsMOJO, reflecting a cautious sentiment regarding the company's current performance.<BR><BR>In summary, while there are some positive signs in terms of profitability, the overall financial results indicate significant challenges that could affect the company's future performance.

What is the technical trend for Soni Medicare?

As of March 17, 2025, Soni Medicare's technical trend is bullish, supported by positive MACD and KST indicators, despite mixed signals from Bollinger Bands and Dow Theory.

As of 17 March 2025, the technical trend for Soni Medicare has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are both bullish, supporting the positive trend. The KST is also bullish on both time frames, reinforcing the bullish stance. While the Bollinger Bands indicate a mildly bullish position on both weekly and monthly charts, the daily moving averages are only mildly bullish. The Dow Theory presents a mixed view, being mildly bearish on the weekly chart but bullish on the monthly chart. Overall, the current technical stance is bullish, with strong support from MACD and KST indicators, despite some mixed signals from other indicators.

Who are the top shareholders of the Soni Medicare?

The top shareholder of Soni Medicare is B R Soni, holding 39.1% of the shares, with Sahil Chabra as the highest public shareholder at 4.69%. Individual investors collectively own 25.15% of the shares, and there are no pledged promoter holdings or institutional investors.

The top shareholders of Soni Medicare include the promoters, with B R Soni holding the highest stake at 39.1%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors holding shares. The highest public shareholder is Sahil Chabra, who owns 4.69%. Additionally, individual investors collectively hold 25.15% of the shares.

Has Soni Medicare declared dividend?

No Dividend History Available